Home > Dermatology > PFGC 2021 > COVID-19: What's New > Patients on immunomodulators need 2 COVID-19 vaccinations before seroconversion

Patients on immunomodulators need 2 COVID-19 vaccinations before seroconversion

Presented By
Dr Ali Al-Janabi, University of Manchester, UK
Conference
PFGC 2021
Encouraging results of 2 recent studies found that almost all patients on immunomodulating treatment for immune-mediated inflammatory diseases (IMID) show antibody positivity after full vaccination. However, in contrast to healthy persons, up to 17% of them do not seroconvert after their first shot of a COVID-19 vaccine. In addition, cellular immune responses are lower in these patients, questioning the durability of antibody response in this patient population. The results of vaccine trials led to a robust knowledge of immune-response in healthy subjects, but less is established about patients on immunomodulatory treatment [1]. “We know that healthy subjects have close to a 100% seroconversion 15–35 days after the first vaccine dose, and if we consider seroconversion as a potential surrogate of vaccine efficacy, we could investigate whether this is the case in patients on immunomodulatory drugs,” Dr Ali Al-Janabi (University of Manchester, UK) pointed out...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on